{"status": "Succeeded", "recognitionResults": [{"page": 1, "clockwiseOrientation": 0.06, "width": 1702, "height": 2238, "unit": "pixel", "lines": [{"boundingBox": [316, 254, 1286, 253, 1287, 281, 317, 282], "text": "Results in supplemental studies with NN622 will indirectly prove appropriateness of our hypothesis.", "words": [{"boundingBox": [317, 255, 387, 255, 388, 281, 318, 280], "text": "Results"}, {"boundingBox": [392, 255, 412, 254, 413, 281, 393, 281], "text": "in"}, {"boundingBox": [418, 254, 547, 254, 547, 282, 418, 281], "text": "supplemental"}, {"boundingBox": [552, 254, 620, 254, 620, 282, 552, 282], "text": "studies"}, {"boundingBox": [625, 254, 667, 254, 668, 282, 625, 282], "text": "with"}, {"boundingBox": [672, 254, 745, 254, 746, 283, 673, 282], "text": "NN622"}, {"boundingBox": [750, 254, 788, 254, 788, 283, 751, 283], "text": "will"}, {"boundingBox": [793, 254, 884, 254, 885, 282, 793, 283], "text": "indirectly"}, {"boundingBox": [889, 254, 946, 254, 946, 282, 890, 282], "text": "prove"}, {"boundingBox": [951, 254, 1105, 255, 1105, 281, 951, 282], "text": "appropriateness"}, {"boundingBox": [1110, 255, 1131, 255, 1131, 281, 1110, 281], "text": "of"}, {"boundingBox": [1136, 255, 1168, 255, 1168, 281, 1136, 281], "text": "our"}, {"boundingBox": [1173, 255, 1287, 255, 1287, 279, 1173, 281], "text": "hypothesis."}]}, {"boundingBox": [316, 286, 909, 288, 908, 317, 315, 315], "text": "No additional actions for Actos and TAK-559 will be required", "words": [{"boundingBox": [317, 288, 347, 288, 347, 314, 316, 314], "text": "No"}, {"boundingBox": [352, 288, 449, 288, 448, 315, 352, 314], "text": "additional"}, {"boundingBox": [454, 289, 523, 289, 523, 315, 453, 315], "text": "actions"}, {"boundingBox": [528, 289, 557, 289, 557, 315, 528, 315], "text": "for"}, {"boundingBox": [562, 289, 618, 289, 618, 316, 562, 315], "text": "Actos"}, {"boundingBox": [623, 289, 661, 288, 660, 316, 623, 316], "text": "and"}, {"boundingBox": [666, 288, 756, 288, 755, 316, 665, 316], "text": "TAK-559"}, {"boundingBox": [761, 288, 798, 288, 797, 317, 760, 316], "text": "will"}, {"boundingBox": [803, 288, 827, 288, 826, 317, 802, 317], "text": "be"}, {"boundingBox": [832, 288, 908, 288, 907, 317, 831, 317], "text": "required"}]}, {"boundingBox": [319, 358, 515, 357, 516, 385, 319, 386], "text": "[Pessimistic views]", "words": [{"boundingBox": [319, 358, 438, 358, 438, 385, 320, 386], "text": "[Pessimistic", "confidence": "Low"}, {"boundingBox": [444, 358, 516, 358, 515, 386, 444, 385], "text": "views]"}]}, {"boundingBox": [320, 390, 935, 391, 934, 419, 319, 418], "text": "Novo Nordisk will think another hypothesis different from ours.", "words": [{"boundingBox": [320, 392, 368, 392, 368, 419, 321, 419], "text": "Novo"}, {"boundingBox": [374, 392, 455, 392, 455, 419, 374, 419], "text": "Nordisk"}, {"boundingBox": [460, 392, 498, 391, 497, 418, 460, 419], "text": "will"}, {"boundingBox": [503, 391, 554, 391, 554, 418, 503, 418], "text": "think"}, {"boundingBox": [560, 391, 630, 391, 630, 418, 559, 418], "text": "another"}, {"boundingBox": [636, 391, 746, 392, 744, 419, 635, 418], "text": "hypothesis"}, {"boundingBox": [751, 392, 831, 392, 829, 419, 750, 419], "text": "different"}, {"boundingBox": [836, 392, 880, 392, 879, 419, 835, 419], "text": "from"}, {"boundingBox": [887, 392, 935, 393, 933, 420, 886, 419], "text": "ours."}]}, {"boundingBox": [320, 426, 1220, 427, 1219, 455, 319, 453], "text": "Novo Nordisk will stop development of NN622 without clarification of possible mechanisms.", "words": [{"boundingBox": [320, 426, 368, 427, 369, 454, 322, 454], "text": "Novo"}, {"boundingBox": [374, 427, 454, 427, 455, 454, 375, 454], "text": "Nordisk"}, {"boundingBox": [460, 427, 496, 427, 497, 454, 461, 454], "text": "will"}, {"boundingBox": [502, 427, 548, 427, 549, 454, 503, 454], "text": "stop"}, {"boundingBox": [553, 427, 674, 428, 675, 454, 554, 454], "text": "development"}, {"boundingBox": [680, 428, 700, 428, 700, 454, 680, 454], "text": "of"}, {"boundingBox": [705, 428, 777, 428, 777, 454, 706, 454], "text": "NN622"}, {"boundingBox": [782, 428, 857, 428, 858, 454, 783, 454], "text": "without"}, {"boundingBox": [863, 428, 978, 429, 978, 454, 863, 454], "text": "clarification"}, {"boundingBox": [984, 429, 1004, 429, 1004, 454, 984, 454], "text": "of"}, {"boundingBox": [1009, 429, 1088, 429, 1088, 455, 1009, 454], "text": "possible"}, {"boundingBox": [1094, 429, 1220, 429, 1220, 455, 1094, 455], "text": "mechanisms."}]}, {"boundingBox": [320, 463, 1205, 462, 1206, 489, 321, 490], "text": "Novo Nordisk will use Actos as a positive control and get some contradictory results to ours.", "words": [{"boundingBox": [321, 463, 370, 464, 370, 489, 321, 489], "text": "Novo"}, {"boundingBox": [375, 464, 457, 464, 457, 490, 375, 489], "text": "Nordisk"}, {"boundingBox": [462, 464, 498, 464, 498, 490, 462, 490], "text": "will"}, {"boundingBox": [503, 464, 536, 464, 536, 490, 503, 490], "text": "use"}, {"boundingBox": [541, 464, 598, 464, 598, 491, 541, 490], "text": "Actos"}, {"boundingBox": [603, 464, 624, 464, 624, 491, 603, 491], "text": "as"}, {"boundingBox": [629, 464, 639, 464, 639, 491, 629, 491], "text": "a"}, {"boundingBox": [644, 464, 722, 464, 722, 491, 644, 491], "text": "positive"}, {"boundingBox": [727, 464, 797, 464, 797, 491, 727, 491], "text": "control"}, {"boundingBox": [802, 464, 837, 464, 836, 491, 801, 491], "text": "and"}, {"boundingBox": [841, 464, 871, 464, 871, 490, 841, 490], "text": "get"}, {"boundingBox": [876, 464, 928, 464, 927, 490, 876, 490], "text": "some"}, {"boundingBox": [933, 464, 1062, 464, 1062, 489, 932, 490], "text": "contradictory"}, {"boundingBox": [1067, 464, 1132, 464, 1131, 488, 1067, 489], "text": "results"}, {"boundingBox": [1137, 464, 1157, 464, 1156, 488, 1136, 488], "text": "to"}, {"boundingBox": [1162, 464, 1205, 464, 1204, 487, 1161, 487], "text": "ours."}]}, {"boundingBox": [313, 498, 1314, 497, 1315, 525, 313, 526], "text": "There will be bladder tumors in a carcinogenicity study of TAK-$59 without any microcrystallines or", "words": [{"boundingBox": [318, 498, 374, 498, 376, 524, 320, 524], "text": "There"}, {"boundingBox": [379, 498, 419, 498, 420, 525, 381, 524], "text": "will"}, {"boundingBox": [424, 498, 450, 498, 451, 525, 426, 525], "text": "be"}, {"boundingBox": [455, 498, 528, 499, 530, 525, 456, 525], "text": "bladder"}, {"boundingBox": [534, 499, 602, 499, 603, 526, 535, 526], "text": "tumors"}, {"boundingBox": [607, 499, 629, 499, 631, 526, 608, 526], "text": "in"}, {"boundingBox": [635, 499, 646, 499, 648, 526, 636, 526], "text": "a"}, {"boundingBox": [652, 499, 801, 499, 802, 526, 653, 526], "text": "carcinogenicity"}, {"boundingBox": [806, 499, 860, 499, 861, 526, 807, 526], "text": "study"}, {"boundingBox": [866, 499, 890, 499, 890, 526, 866, 526], "text": "of"}, {"boundingBox": [895, 499, 987, 499, 988, 526, 896, 526], "text": "TAK-$59", "confidence": "Low"}, {"boundingBox": [992, 499, 1068, 499, 1068, 525, 993, 526], "text": "without"}, {"boundingBox": [1073, 499, 1109, 499, 1109, 525, 1073, 525], "text": "any"}, {"boundingBox": [1114, 499, 1282, 498, 1282, 523, 1114, 525], "text": "microcrystallines"}, {"boundingBox": [1287, 498, 1314, 498, 1314, 523, 1287, 523], "text": "or"}]}, {"boundingBox": [316, 532, 391, 531, 392, 558, 317, 558], "text": "calculi.", "words": [{"boundingBox": [318, 536, 391, 534, 392, 558, 319, 559], "text": "calculi."}]}, {"boundingBox": [321, 600, 1313, 599, 1313, 627, 322, 629], "text": "The authorities including FDA/EMEA may require that we should reconsider our hypothesis in both of", "words": [{"boundingBox": [322, 601, 356, 601, 356, 628, 322, 628], "text": "The"}, {"boundingBox": [361, 601, 462, 601, 462, 628, 361, 628], "text": "authorities"}, {"boundingBox": [467, 601, 560, 601, 560, 628, 467, 628], "text": "including"}, {"boundingBox": [565, 601, 688, 601, 687, 628, 565, 628], "text": "FDA/EMEA"}, {"boundingBox": [693, 601, 735, 601, 735, 628, 693, 628], "text": "may"}, {"boundingBox": [741, 601, 808, 601, 808, 628, 741, 628], "text": "require"}, {"boundingBox": [814, 601, 853, 601, 852, 628, 813, 628], "text": "that"}, {"boundingBox": [858, 601, 886, 601, 886, 628, 858, 628], "text": "we"}, {"boundingBox": [892, 601, 955, 601, 955, 628, 892, 628], "text": "should"}, {"boundingBox": [961, 601, 1062, 601, 1062, 628, 961, 628], "text": "reconsider"}, {"boundingBox": [1067, 601, 1099, 600, 1099, 628, 1067, 628], "text": "our"}, {"boundingBox": [1105, 600, 1209, 600, 1209, 627, 1104, 627], "text": "hypothesis"}, {"boundingBox": [1215, 600, 1234, 600, 1234, 627, 1215, 627], "text": "in"}, {"boundingBox": [1239, 600, 1284, 599, 1284, 627, 1239, 627], "text": "both"}, {"boundingBox": [1289, 599, 1312, 599, 1312, 627, 1289, 627], "text": "of"}]}, {"boundingBox": [322, 634, 1124, 635, 1123, 663, 321, 662], "text": "Actos and TAK-559 based on Novo Nordisk's hypothesis or find other hypotheses.", "words": [{"boundingBox": [323, 635, 375, 635, 374, 661, 322, 661], "text": "Actos"}, {"boundingBox": [380, 635, 417, 635, 416, 662, 379, 661], "text": "and"}, {"boundingBox": [422, 635, 513, 635, 512, 663, 421, 662], "text": "TAK-559"}, {"boundingBox": [518, 635, 575, 635, 574, 663, 517, 663], "text": "based"}, {"boundingBox": [580, 635, 603, 635, 603, 663, 579, 663], "text": "on"}, {"boundingBox": [608, 635, 664, 635, 663, 664, 608, 663], "text": "Novo"}, {"boundingBox": [669, 635, 763, 635, 762, 664, 668, 664], "text": "Nordisk's"}, {"boundingBox": [768, 635, 872, 635, 871, 664, 767, 664], "text": "hypothesis"}, {"boundingBox": [877, 635, 898, 635, 898, 664, 876, 664], "text": "or"}, {"boundingBox": [903, 635, 942, 635, 942, 664, 903, 664], "text": "find"}, {"boundingBox": [947, 635, 996, 635, 995, 663, 947, 663], "text": "other"}, {"boundingBox": [1001, 635, 1123, 635, 1123, 662, 1000, 663], "text": "hypotheses."}]}, {"boundingBox": [318, 670, 1315, 671, 1314, 700, 317, 699], "text": "In worst case, when Novo Nordisk will stop its development for this reason, the regulatory authorities", "words": [{"boundingBox": [318, 671, 340, 671, 340, 697, 318, 697], "text": "In"}, {"boundingBox": [345, 671, 400, 671, 401, 698, 345, 697], "text": "worst"}, {"boundingBox": [406, 671, 454, 671, 455, 698, 406, 698], "text": "case,"}, {"boundingBox": [460, 671, 512, 671, 512, 699, 460, 698], "text": "when"}, {"boundingBox": [517, 671, 573, 671, 573, 699, 517, 699], "text": "Novo"}, {"boundingBox": [578, 671, 659, 671, 659, 700, 578, 699], "text": "Nordisk"}, {"boundingBox": [664, 671, 702, 671, 702, 700, 664, 700], "text": "will"}, {"boundingBox": [707, 671, 750, 671, 749, 700, 707, 700], "text": "stop"}, {"boundingBox": [755, 671, 782, 671, 781, 700, 754, 700], "text": "its"}, {"boundingBox": [787, 671, 910, 671, 909, 700, 786, 700], "text": "development"}, {"boundingBox": [915, 671, 944, 671, 943, 700, 914, 700], "text": "for"}, {"boundingBox": [949, 671, 984, 671, 983, 700, 948, 700], "text": "this"}, {"boundingBox": [989, 671, 1062, 671, 1061, 700, 989, 700], "text": "reason,"}, {"boundingBox": [1067, 671, 1097, 671, 1096, 700, 1066, 700], "text": "the"}, {"boundingBox": [1102, 671, 1205, 671, 1204, 699, 1101, 700], "text": "regulatory"}, {"boundingBox": [1210, 671, 1315, 671, 1313, 698, 1209, 699], "text": "authorities"}]}, {"boundingBox": [321, 705, 1316, 702, 1317, 732, 322, 735], "text": "may not allow us to sell Actos or to continue clinical studies of TAK-559 until we can clarify the", "words": [{"boundingBox": [322, 707, 362, 707, 362, 734, 322, 734], "text": "may"}, {"boundingBox": [367, 707, 403, 707, 404, 734, 368, 734], "text": "not"}, {"boundingBox": [409, 707, 462, 707, 463, 734, 409, 734], "text": "allow"}, {"boundingBox": [471, 707, 497, 707, 498, 735, 472, 734], "text": "us"}, {"boundingBox": [502, 707, 527, 707, 527, 735, 503, 735], "text": "to"}, {"boundingBox": [532, 707, 568, 706, 569, 735, 533, 735], "text": "sell"}, {"boundingBox": [574, 706, 633, 706, 633, 735, 574, 735], "text": "Actos"}, {"boundingBox": [638, 706, 662, 706, 663, 735, 639, 735], "text": "or"}, {"boundingBox": [667, 706, 692, 706, 692, 735, 668, 735], "text": "to"}, {"boundingBox": [697, 706, 782, 706, 783, 735, 698, 735], "text": "continue"}, {"boundingBox": [787, 706, 864, 705, 865, 734, 788, 735], "text": "clinical"}, {"boundingBox": [869, 705, 938, 705, 939, 734, 870, 734], "text": "studies"}, {"boundingBox": [944, 705, 970, 705, 971, 734, 944, 734], "text": "of"}, {"boundingBox": [975, 705, 1069, 704, 1070, 734, 976, 734], "text": "TAK-559"}, {"boundingBox": [1074, 704, 1124, 704, 1125, 734, 1075, 734], "text": "until"}, {"boundingBox": [1130, 704, 1161, 704, 1162, 733, 1130, 733], "text": "we"}, {"boundingBox": [1166, 704, 1204, 704, 1205, 733, 1167, 733], "text": "can"}, {"boundingBox": [1209, 704, 1274, 704, 1275, 733, 1210, 733], "text": "clarify"}, {"boundingBox": [1279, 704, 1315, 703, 1316, 732, 1280, 733], "text": "the"}]}, {"boundingBox": [317, 739, 588, 742, 588, 771, 316, 768], "text": "mechanisms of the tumors.", "words": [{"boundingBox": [317, 742, 438, 741, 438, 768, 317, 767], "text": "mechanisms"}, {"boundingBox": [443, 741, 464, 741, 464, 769, 443, 768], "text": "of"}, {"boundingBox": [469, 741, 499, 742, 499, 769, 469, 769], "text": "the"}, {"boundingBox": [504, 742, 586, 743, 586, 771, 504, 769], "text": "tumors."}]}, {"boundingBox": [320, 809, 457, 810, 456, 839, 319, 837], "text": "[Other views]", "words": [{"boundingBox": [320, 810, 389, 811, 389, 839, 321, 839], "text": "[Other", "confidence": "Low"}, {"boundingBox": [394, 811, 457, 811, 457, 839, 395, 839], "text": "views]"}]}, {"boundingBox": [318, 843, 1320, 842, 1320, 872, 319, 872], "text": "Novo Nordisk expect the filing for approval to be delayed by close to 2 years. If only this tumor", "words": [{"boundingBox": [319, 844, 374, 844, 375, 872, 320, 872], "text": "Novo"}, {"boundingBox": [379, 844, 462, 843, 463, 872, 380, 872], "text": "Nordisk"}, {"boundingBox": [468, 843, 532, 843, 532, 872, 469, 872], "text": "expect"}, {"boundingBox": [537, 843, 571, 843, 572, 872, 538, 872], "text": "the"}, {"boundingBox": [577, 843, 633, 843, 634, 871, 577, 872], "text": "filing"}, {"boundingBox": [639, 843, 671, 843, 671, 871, 639, 871], "text": "for"}, {"boundingBox": [677, 843, 763, 843, 763, 871, 677, 871], "text": "approval"}, {"boundingBox": [769, 843, 789, 843, 790, 871, 769, 871], "text": "to"}, {"boundingBox": [795, 843, 825, 843, 825, 871, 795, 871], "text": "be"}, {"boundingBox": [831, 843, 904, 843, 904, 871, 831, 871], "text": "delayed"}, {"boundingBox": [910, 843, 938, 843, 938, 871, 910, 871], "text": "by"}, {"boundingBox": [944, 843, 996, 843, 996, 871, 943, 871], "text": "close"}, {"boundingBox": [1002, 843, 1024, 843, 1024, 872, 1002, 872], "text": "to"}, {"boundingBox": [1030, 843, 1045, 843, 1045, 872, 1030, 872], "text": "2"}, {"boundingBox": [1051, 843, 1122, 843, 1122, 872, 1051, 872], "text": "years."}, {"boundingBox": [1132, 843, 1152, 843, 1152, 872, 1131, 872], "text": "If"}, {"boundingBox": [1158, 843, 1203, 843, 1203, 872, 1158, 872], "text": "only"}, {"boundingBox": [1209, 843, 1246, 843, 1246, 872, 1208, 872], "text": "this"}, {"boundingBox": [1252, 843, 1320, 843, 1319, 872, 1251, 872], "text": "tumor"}]}, {"boundingBox": [317, 878, 1318, 879, 1317, 907, 316, 907], "text": "issue does matter, 2 years until its NDA submission seem to be too long if it is set only for clarification", "words": [{"boundingBox": [317, 879, 371, 879, 371, 907, 317, 908], "text": "issue"}, {"boundingBox": [376, 879, 417, 879, 417, 907, 376, 907], "text": "does"}, {"boundingBox": [423, 879, 491, 879, 491, 907, 423, 907], "text": "matter,"}, {"boundingBox": [497, 879, 508, 879, 508, 907, 497, 907], "text": "2"}, {"boundingBox": [513, 879, 565, 879, 565, 907, 513, 907], "text": "years"}, {"boundingBox": [571, 879, 615, 879, 615, 907, 571, 907], "text": "until"}, {"boundingBox": [621, 879, 645, 879, 645, 907, 621, 907], "text": "its"}, {"boundingBox": [651, 879, 702, 879, 702, 907, 650, 907], "text": "NDA"}, {"boundingBox": [708, 879, 816, 879, 815, 906, 708, 906], "text": "submission"}, {"boundingBox": [821, 879, 869, 879, 869, 906, 821, 906], "text": "seem"}, {"boundingBox": [875, 879, 895, 879, 895, 906, 875, 906], "text": "to"}, {"boundingBox": [901, 879, 925, 879, 925, 906, 900, 906], "text": "be"}, {"boundingBox": [931, 879, 960, 879, 960, 906, 930, 906], "text": "too"}, {"boundingBox": [966, 879, 1010, 879, 1010, 906, 965, 906], "text": "long"}, {"boundingBox": [1016, 879, 1031, 879, 1030, 906, 1015, 906], "text": "if"}, {"boundingBox": [1036, 879, 1051, 879, 1051, 906, 1036, 906], "text": "it"}, {"boundingBox": [1057, 879, 1073, 879, 1073, 907, 1056, 906], "text": "is"}, {"boundingBox": [1079, 879, 1107, 879, 1106, 907, 1078, 907], "text": "set"}, {"boundingBox": [1112, 879, 1157, 879, 1156, 907, 1112, 907], "text": "only"}, {"boundingBox": [1162, 879, 1190, 879, 1189, 907, 1162, 907], "text": "for"}, {"boundingBox": [1196, 879, 1318, 880, 1317, 907, 1195, 907], "text": "clarification"}]}, {"boundingBox": [322, 913, 1311, 914, 1310, 943, 321, 942], "text": "of the mechanism. Therefore, we may guess that NN622 might have other issues in clinical trials and", "words": [{"boundingBox": [322, 914, 338, 914, 339, 942, 323, 941], "text": "of"}, {"boundingBox": [344, 914, 374, 914, 375, 942, 344, 942], "text": "the"}, {"boundingBox": [379, 914, 508, 915, 509, 942, 380, 942], "text": "mechanism."}, {"boundingBox": [523, 915, 623, 915, 623, 943, 523, 943], "text": "Therefore,"}, {"boundingBox": [628, 915, 655, 915, 655, 943, 628, 943], "text": "we"}, {"boundingBox": [660, 915, 703, 915, 704, 943, 661, 943], "text": "may"}, {"boundingBox": [709, 915, 762, 916, 763, 943, 709, 943], "text": "guess"}, {"boundingBox": [768, 916, 803, 916, 804, 943, 768, 943], "text": "that"}, {"boundingBox": [809, 916, 880, 916, 881, 943, 809, 943], "text": "NN622"}, {"boundingBox": [886, 915, 941, 915, 941, 943, 886, 943], "text": "might"}, {"boundingBox": [947, 915, 995, 915, 995, 943, 947, 943], "text": "have"}, {"boundingBox": [1000, 915, 1050, 915, 1051, 943, 1000, 943], "text": "other"}, {"boundingBox": [1056, 915, 1115, 915, 1115, 943, 1056, 943], "text": "issues"}, {"boundingBox": [1120, 915, 1140, 915, 1140, 943, 1120, 943], "text": "in"}, {"boundingBox": [1145, 915, 1217, 915, 1217, 943, 1145, 943], "text": "clinical"}, {"boundingBox": [1222, 914, 1270, 914, 1270, 942, 1222, 943], "text": "trials"}, {"boundingBox": [1276, 914, 1310, 914, 1310, 942, 1276, 942], "text": "and"}]}, {"boundingBox": [320, 948, 1318, 948, 1318, 978, 321, 979], "text": "\"urinary bladder tumor\" is used just as a scapegoat or that Novo Nordisk virtually give up the", "words": [{"boundingBox": [321, 950, 405, 950, 405, 977, 322, 976], "text": "\"urinary", "confidence": "Low"}, {"boundingBox": [410, 950, 489, 950, 489, 978, 411, 977], "text": "bladder"}, {"boundingBox": [494, 950, 569, 950, 570, 978, 495, 978], "text": "tumor\""}, {"boundingBox": [575, 950, 597, 950, 598, 978, 575, 978], "text": "is"}, {"boundingBox": [603, 950, 651, 950, 652, 979, 603, 978], "text": "used"}, {"boundingBox": [657, 950, 700, 950, 701, 979, 657, 979], "text": "just"}, {"boundingBox": [706, 950, 732, 950, 732, 979, 706, 979], "text": "as"}, {"boundingBox": [737, 950, 754, 950, 755, 979, 737, 979], "text": "a"}, {"boundingBox": [760, 950, 861, 950, 861, 979, 760, 979], "text": "scapegoat"}, {"boundingBox": [866, 950, 891, 950, 891, 979, 867, 979], "text": "or"}, {"boundingBox": [896, 950, 938, 950, 938, 979, 896, 979], "text": "that"}, {"boundingBox": [943, 950, 1003, 950, 1003, 979, 944, 979], "text": "Novo"}, {"boundingBox": [1008, 950, 1092, 950, 1092, 979, 1008, 979], "text": "Nordisk"}, {"boundingBox": [1100, 949, 1188, 949, 1188, 978, 1101, 979], "text": "virtually"}, {"boundingBox": [1193, 949, 1240, 949, 1241, 978, 1193, 978], "text": "give"}, {"boundingBox": [1245, 949, 1273, 948, 1274, 978, 1246, 978], "text": "up"}, {"boundingBox": [1280, 948, 1317, 948, 1318, 977, 1281, 978], "text": "the"}]}, {"boundingBox": [322, 985, 456, 987, 455, 1012, 321, 1011], "text": "development.", "words": [{"boundingBox": [324, 986, 455, 987, 456, 1012, 324, 1010], "text": "development."}]}, {"boundingBox": [1164, 1790, 1319, 1791, 1319, 1814, 1163, 1813], "text": "2002/7/24 DSRL", "words": [{"boundingBox": [1166, 1791, 1254, 1791, 1254, 1813, 1166, 1813], "text": "2002/7/24"}, {"boundingBox": [1258, 1791, 1315, 1791, 1315, 1814, 1259, 1813], "text": "DSRL"}]}, {"boundingBox": [142, 1925, 554, 1925, 553, 1951, 141, 1950], "text": "Confidential - Subject to Protective Order", "words": [{"boundingBox": [142, 1925, 255, 1927, 256, 1951, 143, 1951], "text": "Confidential"}, {"boundingBox": [260, 1927, 276, 1927, 277, 1951, 261, 1951], "text": "-"}, {"boundingBox": [281, 1927, 354, 1928, 355, 1950, 282, 1951], "text": "Subject"}, {"boundingBox": [360, 1928, 379, 1928, 379, 1950, 360, 1950], "text": "to"}, {"boundingBox": [384, 1928, 483, 1927, 484, 1950, 384, 1950], "text": "Protective"}, {"boundingBox": [488, 1927, 553, 1926, 553, 1950, 489, 1950], "text": "Order"}]}, {"boundingBox": [1224, 1923, 1475, 1926, 1474, 1952, 1223, 1948], "text": "TAK-THOMCL-00019814", "words": [{"boundingBox": [1227, 1923, 1473, 1928, 1475, 1951, 1228, 1949], "text": "TAK-THOMCL-00019814"}]}, {"boundingBox": [1224, 1954, 1542, 1956, 1541, 1985, 1223, 1983], "text": "Produced in MDL on 09/14/12", "words": [{"boundingBox": [1226, 1955, 1327, 1956, 1327, 1983, 1226, 1983], "text": "Produced"}, {"boundingBox": [1332, 1956, 1352, 1956, 1352, 1983, 1332, 1983], "text": "in"}, {"boundingBox": [1358, 1956, 1409, 1956, 1409, 1983, 1358, 1983], "text": "MDL"}, {"boundingBox": [1414, 1956, 1442, 1956, 1441, 1984, 1414, 1983], "text": "on"}, {"boundingBox": [1447, 1956, 1542, 1956, 1542, 1986, 1447, 1984], "text": "09/14/12"}]}, {"boundingBox": [385, 2194, 1318, 2193, 1318, 2232, 386, 2234], "text": "Source: https://www.indup2298-00002ts.ucsf.edu/docs/zyjf0226", "words": [{"boundingBox": [388, 2195, 500, 2196, 500, 2232, 388, 2230], "text": "Source:"}, {"boundingBox": [507, 2196, 1318, 2193, 1318, 2230, 507, 2232], "text": "https://www.indup2298-00002ts.ucsf.edu/docs/zyjf0226", "confidence": "Low"}]}]}]}